Doctors use the PSEN2 genetic test to confirm familial early-onset Alzheimer disease when memory or thinking symptoms progress before age 65 and family history suggests an inherited pattern. PSEN2 is a gene where a harmful change can cause Alzheimer's passed in families, and doctors order it with APP and PSEN1 testing. Federal guidance notes genetic tests are not routine for Alzheimer diagnosis, according to the Alzheimers.gov fact sheet from the National Institute on Aging genetics and family history fact sheet. A neurologist may still order APP, PSEN1, and PSEN2 testing when early-age symptoms pair with a strong family history.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- When doctors order testing during progression
- What a positive result means for outlook
- What the test does not change
- Counseling and practical next steps for families
When doctors order testing during progression
Doctors usually consider testing after a clinical exam, cognitive testing, and brain workup point toward early-onset Alzheimer disease. The key triggers are onset before 65 and relatives across generations with similar early dementia.
The American College of Medical Genetics and National Society of Genetic Counselors joint guidelines recommend APP, PSEN1, and PSEN2 testing in this setting to confirm familial diagnosis 2011 evaluation guidelines. Clinical guidance from ARUP Laboratories directs doctors to use the early-onset panel to confirm diagnosis in symptomatic patients or for at-risk relatives, not when symptoms began after 65 early-onset panel guidance.
What a positive result means for outlook
A positive PSEN2 harmful variant explains early-onset Alzheimer type 4. Onset is typically 40 to 75 years, with about 95 percent lifetime penetrance, meaning most carriers develop dementia. PSEN2 accounts for only about 5 percent of early-onset familial Alzheimer cases.
Mean disease duration is around 11 years, but progression varies and carriers over age 80 without symptoms have been reported, according to the University of Washington GeneReviews Alzheimer disease overview. For a patient with worsening symptoms, the result clarifies cause more than daily care. It helps the doctor explain likely course, plan support needs, and watch for rapid changes.
What the test does not change
The test does not diagnose Alzheimer by itself and does not guide most drug choices. Doctors still track symptoms, function, safety, and other medical causes during follow-up visits.
A negative result also has limits. It does not rule out Alzheimer disease, especially without a known family variant. Other genes, mixed causes, or non-Alzheimer dementia may still explain progression.
Counseling and practical next steps for families
Guidelines require pre-test and post-test genetic counseling with informed consent and referral to familial-dementia expertise. Predictive APP, PSEN1, and PSEN2 testing is not done in children under 18, according to the NCRAD genetics summary genetic testing guidance.
When a family mutation is found, doctors can take clear next steps. These referrals give families access to monitoring and trials built for inherited Alzheimer disease, according to the National Institute on Aging trial program DIAN trial information.
- Clarify prognosis and care planning for the patient
- Offer risk counseling and monitoring options to adult relatives
- Discuss reproductive choices for carriers
- Refer eligible carriers to prevention research such as the Dominantly Inherited Alzheimer Network
